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Background: Benefit of treatment with the monoclonal anti-IgE-antibody omalizumab in severe
IgE-dependent asthma requires a significant reduction of serum free IgE concentrations. It is
unclear if monitoring free serum IgE is clinically meaningful once omalizumab treatment is
initiated.
Methods: Free IgE and omalizumab serum concentrations were quantified in 22 patients with
severe asthma (68% female, 47  11 yrs, mean (SD) pre-bronchodilator FEV1 62  13%, base-
line mean (SEM) free serum IgE 652  136 ng/ml) treated with omalizumab for 4 months using
a Recovery-ELISA.
Results: Omalizumab treatment reduced free serum IgE prior to the second omalizumab injec-
tion by 73%, after 16 weeks by 81% to 58  12 ng/ml (p < 0.001 vs. baseline). 17 patients re-
sponded to anti-IgE therapy as judged by physician-rated global evaluation of treatment
effectiveness. There was neither a relation between free serum IgE concentrations and treat-
ment response nor a significant or clinically relevant correlation between free IgE levels and
changes in lung function, exhaled NO, asthma control, and quality of life. Serum concentra-
tions of omalizumab were detected in all patients and reached a stable phase within 8 weeks.
Conclusions: Monitoring free IgE and omalizumab serum concentrations in patients treated
with omalizumab does not predict clinical response nor does it add to the decision to continue
or stop treatment. However, routine measurements of free IgE may be clinically relevant to
demonstrate an adequate reduction in free IgE in patients not responding to omalizumab
therapy.
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perennial allergens tested as part of our standard allergenImmunoglobulin E (IgE) is central to the pathophysiological
cascade that eventually triggers allergic reactions and
perpetuates bronchial airway inflammation.1 Consequently,
omalizumab, a recombinant humanized monoclonal anti-
IgE antibody, has been approved as add-on treatment for
patients with inadequately controlled severe persistent
IgE-dependent allergic asthma despite GINA step 4
therapies.2e4 Omalizumab interrupts the allergic cascade
by binding to the Fc region of free serum IgE. Free IgE
serum concentrations are rapidly reduced, the expression
of the high affinity IgE receptor (Fc 3RI) on inflammatory
cells down regulated, and mast cell and basophil activation
and subsequent release of their inflammatory mediators
inhibited.5,6 In patients with allergic asthma and poor
disease control despite best available therapy omalizumab
as add-on therapy reduced asthma symptoms, clinically
significant asthma exacerbations, emergency visits and
hospitalizations due to asthma in clinical trials as well as in
real-life settings.5,7,8 The ability of omalizumab to lower
free IgE in serum depends on dose, the patients’ body
weight and baseline total serum IgE level. Clinical trials
suggest that benefit with omalizumab is observed when
serum free IgE concentrations are reduced to 50 ng/ml
(20.8 IU/ml) or less.9,10 Omalizumab and IgE molecules
form small, biologically inactive complexes.11,12 Commer-
cially available assays to quantify IgE recognize both free
IgE and IgE molecules that are part of omalizumab-IgE-
complexes, making it impossible to monitor free serum
IgE once omalizumab treatment is initiated. Thus, the
decision if omalizumab is effective is solely based on the
physicians’ judgement.13 Long-term treatment adjustments
aimed at the treatment target, free IgE, are not feasible.
To overcome this problem a newly available Recovery-ELISA
was used to quantify free serum IgE in patients before and
during treatment with omalizumab. Serum concentrations
of free IgE and omalizumab were measured and correlated
with markers of asthma control.Methods
Patients
22 patients with uncontrolled severe persistent asthma
were selected for add-on therapy with omalizumab as
recommended by national14 and international guidelines.2
All patients had a physician-diagnosed asthma with either
documented variable airflow obstruction, increase in FEV1
of more than 12% and 200 ml after 200 mg of salbutamol
and/or a methacholine PC20 of <8 mg/ml. Further inclu-
sion criteria were a reduced lung function (FEV1 < 80%
pred.), the diagnosis of severe persistent uncontrolled
asthma as indicated by frequent daily symptoms or
nocturnal awakenings and severe asthma exacerbations
despite treatment with high doses of inhaled corticoste-
roids (>500 mg BDP or equivalent/day) and long-acting b2-
agonists. All except one patient were sensitized to at least
one perennial allergen as documented by positive skin prick
test or in vitro reactivity. One patient neither showed skinprick test reactivity nor specific IgE against common
panel. However, all clinical entry criteria were fulfilled and
total serum IgE was slightly elevated (104 IU/ml) within the
dosing range of omalizumab. The patient was included in
the trial without further attempts to identify a sensitization
to rare perennial allergens. All except one patient had
levels of total serum IgE and body weight within the oma-
lizumab dosing table15 and were treated accordingly.
A third patient slightly outside the dosing range (843 IU/ml,
86 kg) was treated with the maximal approved omalizumab
dose (750 mg/month).
Exclusion criteria were current smoking, a serious
coexisting illness, and the possibility of conception. All
patients included in the study provided written informed
consent. The study was performed according to Good
Clinical Practice standards and the declaration of Helsinki
and was approved by the local ethics committees and the
Paul-Ehrlich Institute, an agency of the German Federal
Ministry of Health.
Study design
In this single center clinical trial patients were seen
between 2 and 4 weeks prior to start of treatment for
a screening visit to confirm eligibility for omalizumab and to
assess demographics. Patients were treated with omalizu-
mab subcutaneously according to the dosing table and
were followed-up every 2 weeks (total omalizumab
doses > 300 mg/month; n Z 13) or 4 weeks (total
dose  300 mg/month) for their omalizumab injections and
study visits for a total of 16 weeks. Due to its specific
mechanism of action, it is recommended to assess omali-
zumab effectiveness after 16 weeks of treatment.15 Serum
samples to quantify free IgE and omalizumab concentra-
tions were collected prior to (trough) and 1 h after each
omalizumab injection at all visits.
In addition, the following procedures were performed at
each study visit: pre- and post-bronchodilator spirometry
(according to ATS/ERS criteria Jaeger Masterscreen Body,
Hoechberg, Germany), measurements of exhaled NO
according to ATS guidelines (Niox Mino, Aerocrine, Solna,
Sweden) as well as evaluations of global treatment effec-
tiveness (GETE: complete control, marked improvement in
control, discernible but limited control, no appreciable
change, worsening in control),16 asthma control (ACQ-5)17
and quality of life (Mini-AQLQ).18 The minimal clinically
important difference in ACQ-5 and Mini-AQLQ scores is 0.5.
Changes in medication were allowed to adjust treatment
based on the patients’ asthma control. During the trial the
patients and investigators were blinded to results of the
free IgE and omalizumab assays.
Quantification of free serum IgE and omalizumab
concentrations
Free serum IgE and omalizumab concentrations were
quantified with a commercially available Recovery-ELISA kit
by the manufacturer (Patent EP1957980, BioTeZ Berlin-
Buch, Germany) according to ISO9001 and the rules of
Good Laboratory Practice.19,20 The Recovery-ELISA is
Table 1 Demographic and baseline clinical characteristics
of study participants.
Age (years) 47.3  11.4 (21.5e65.1)
Female sex (n, %) 15, 68%
Total serum IgEa (IU/ml) 263 (139e418; 42e843)
Body weight (kg) 79.6  12.3 (50.0e93.0)
Omalizumab dose (mg/month) 600 (300e600; 150e750)
Pre bronchodilator FEV1
a (L) 1.96  0.55 (0.93e2.95)
% of predicted normal 61.8  13.1 (33.0e79.7)
Post bronchodilator FEV1
a (L) 2.09  0.50 (1.17e2.91)
% of predicted normal 64.8  11.4 (40.0e78.7)
Exhaled NO (ppb) 40  29 (8e108)
Asthma control (ACQ-5) 3.0  1.2 (0.2e4.8)
Quality of Life (Mini-AQLQ) 3.6  1.3 (1.8e6.5)
Inhaled corticosteroidsb
(mg/day)
1000 (1000e2000;
500e4000)
Use of oral corticosteroids
(n, %)
9, 21%
Dose of oral prednisolone
(mg/day)
12.5 (10e17.5; 8e40)
Plus-minus values are means  SD (range), all other values are
medians, interquartile ranges and minimumemaximum. Values
are those recorded at baseline (week 0). FEV1 denotes forced
expiratory volume in 1 s. NO denotes nitric oxide in exhaled air.
a Total serum IgE and FEV1 values were obtained prior to
baseline (screening visit).
b The doses of inhaled corticosteroid were converted to the
equivalent dose of beclomethasone dipropionate.
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Using standard serum samples spiked with IgE and omali-
zumab in a defined concentration range standard curves
and reference functions were created for samples with or
without omalizumab, respectively. This multi-dimensional
calibration procedure enables the simultaneous measure-
ment of free IgE and omalizumab in serum samples of
patients treated with omalizumab. In undiluted serum the
Recovery-ELISA is able to assay for free IgE in a concentra-
tion range of 1e2000 IU/ml in samples without omalizumab
and of 1e500 IU/ml in samples containing omalizumab as
well as for omalizumab in a range of 0.4e80 mg/ml. Inter-
and intra-variability of the assay were between 3.2 and
12.1% (coefficient of variation) for free IgE and between 6.9
and 14.4% for omalizumab. All serum samples were frozen
immediately and kept in a 80 C freezer until assayed for
free IgE.
Statistical analysis
The primary outcome parameter was the correlation of free
IgE with treatment effectiveness rated by the physician
based on the GETE scale.16 Patients with complete or
marked improvement in asthma control were considered
responders. Secondary outcome measures were change in
lung function, exhaled NO, asthma control and quality of
life after 16 weeks of treatment as well as the relation of
free serum IgE to these parameters.
Sample size was calculated based on the primary
outcome parameter. In clinical trials free IgE was reduced
below the therapeutic target of 50 ng/ml in approximately
90e95% of patients treated with omalizumab, and the
responder rate was 60e75%.8e10,21e23 With p-values < 0.05
indicating statistical significance of 22 patients were
calculated as appropriate for the study.
Data description was primarily based on means and
standard deviation or standard error of mean or medians
and quartiles (interquartile ranges) for continuous
endpoints (e.g., free IgE), and on frequencies for categor-
ical endpoints (e.g., responder vs. non-responder).
Comparisons between patient subpopulations were based
on Wilcoxon or t-test for continuous endpoints and on
Fishers exact test for categorical endpoints. Intraindividual
comparisons were based on sign or paired t-test. A logistic
regression model was used for multivariate analyses. Data
analysis was performed using SPSS 11.5 software for
Windows.
Results
Clinical response to omalizumab
22 patients with a physician-diagnosed severe persistent
asthma (Table 1) were treated prospectively with omali-
zumab for 16 weeks. At the end of the study period efficacy
of omalizumab was rated by GETE as complete or marked
improvement in control in 17 patients (77%, responders). In
the remaining 5 patients the treatment offered no clinical
benefit.
At the end of the study period lung function had
improved in 12 of 17 patients who responded toomalizumab treatment. The exhaled NO had decreased in
10 of the 17 patients, and oral corticosteroids could be
reduced or withdrawn in 5 of the 7 responders who had
been on oral corticosteroids prior to study. ICS doses were
unchanged in 10, could be reduced in 3 and had to be
increased in 4 patients (median change 0 mg/day). Asthma
control and/or quality of life had improved significantly
(ACQ-5 p < 0.001, AQLQ p Z 0.001) in all responders
(Table 2). In contrast, no clinically relevant changes were
seen in the 5 non-responders, including doses of inhaled
and/or oral corticosteroids. Further, in a logistic regression
model among all covariables treatment response to omali-
zumab was significantly associated only with an ACQ
improvement of more than 0.5 points (p Z 0.010), not
surprising given that ACQ and GETE questionnaires both
probe for subjective symptomatic improvements. The
variables recorded as part of the present trial cannot
predict response to omalizumab treatment. Doses of
inhaled corticosteroids were unchanged in non-responders
(median change 0 mg/day, range 500e0 mg/day BDP or
equivalent).
Free IgE and omalizumab serum concentrations
One hour after the first omalizumab injection free serum
IgE was slightly reduced (Table 3). Prior to the second
injection trough free serum IgE was reduced in all patients
by 73% (Fig. 1). After 4 weeks of treatment, independent of
baseline IgE and omalizumab dose, trough free IgE was
below 100 ng/ml in all but three patients (102, 102, and
270 ng/ml). Concentrations remained low for the rest of
Table 2 Responder status and clinical parameters.
Change: week 16 vs. baseline Responder Non-responder p-value
Free serum IgE (% reduction) 79  6 (4e98) 70  13 (29e98) 0.537
FEV1 (L) 0.1  0.1 (1.4e1.1) 0.1  0.1 (0.3e0.2) 0.212
FEV1 (% of. pred.) 3.8  3.8 (36.8e26.3) 2.1  3.2 (9.7e5.7) 0.249
Exhaled NO (ppb) 5  8 (53e70) 6  7 (14e24) 0.305
ACQ5 1.7  0.4 (3.6e2.8) 0.1  0.1 (0.2e0.6) <0.001
Mini-AQLQ 1.9  0.4 (1.8e3.7) 0.1  0.2 (0.5e0.9) 0.001
Parameter at week 16
Free serum IgE (ng/ml) 58  16 (7e272) 61  12 (36e102) 0.869
Free serum IgE < 50 ng/ml (n, %) 10, 59% 2, 40% 0.624
Omalizumab concentration (mg/ml) 45  8 (5e140) 22  5 (9e36) 0.189
Values are means  SEM (range) unless otherwise stated. FEV1 denotes forced expiratory volume in 1 s. Exhaled NO denotes nitric oxide
in exhaled air. p-values: responders vs. non-responders.
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in 21 patients by 81% (Table 3). In one patient (responder)
free IgE was unchanged (baseline 45 ng/ml, 16 weeks
47 ng/ml).
There was no relation between free serum IgE concen-
trations and treatment effectiveness (GETE) after 16 weeks
of treatment. In particular, free serum IgE levels were
similar in responders and non-responders despite significant
and/or clinically relevant differences in lung function,
exhaled NO, asthma control, and quality of life (Table 2).
Omalizumab was detected in serum in 21 patients after
the first injection and in all patients after 16 weeks of
treatment (Table 3). Serum concentrations of free IgE and
omalizumab reached a stable phase within 8 weeks, with no
significant difference between responders and non-
responders (Table 3).
Discussion
The treatment of severe allergic asthma with a humanized
monoclonal anti-IgE antibody is supported by results of
multiple phase IIeIV clinical trials in the adult and pediatric
population.3,4,7,8,16,23,24 The results of the present studyTable 3 Free serum IgE and omalizumab concentrations.
Mean  SEM p-value
(vs. baseline)
Free serum IgE (ng/ml)
Baseline (week 0) 652  136 (45e2078) e
Change 1 h after
first injection
57  26 (300e105) 0.039
Trough second
injection
108  19 (8e309) <0.001
Trough 16 weeks of
treatment
58  12 (7e272) <0.001
Omalizumab (mg/ml)
Trough second
injection
18  3 (0e55) <0.001
Trough 16 weeks
of treatment
40  7 (5e>140) <0.001confirm that a majority of patients with severe allergic
asthma characterized by compromised lung function and
frequent exacerbations despite treatment with high doses
of inhaled glucocorticosteroids and long-acting b2-agonists
benefit from treatment with anti-IgE. Omalizumab reduced
serum concentrations of free IgE to levels in the same range
as were reported as part of the omalizumab phase IIeIV
clinical trial program. In addition, the present study
demonstrated for the first time outside of clinical trials
organized by the manufacturer of omalizumab that moni-
toring of serum concentrations of free IgE and omalizumab
with a commercially available assay is feasible, and that
anti-IgE treatment decreased serum concentrations of free
IgE around 10-fold.
The therapeutic efficacy of omalizumab is mainly
attributed to a reduction of free IgE secondary to the
formation of IgE-anti-IgE immune complexes, thereby pre-
venting downstream immunological reactions that eventu-
ally lead to allergic and asthmatic symptoms.9,25 To simplify
dosing, and ensure that free IgE reduction is achieved, an
individualized tiered dosing table was developed based on
phase II studies in which free serum IgE concentrations
were quantified,9,26 and in which patients, depending on
weight and baseline IgE level, received omalizumab by
subcutaneous injection every 2 or 4 weeks. Commercially
available IgE assays recognize IgE-anti-IgE immune
complexes, leading to false IgE measurements in patients
treated with omalizumab.27 Until recently it was impossible
to routinely quantify free serum IgE as a means to guide
long-term omalizumab dosing and monitor treatment. This
trial addresses several of the ensuing questions and
demonstrates that free IgE and omalizumab serum
concentrations can be routinely monitored in asthma
patients on omalizumab. Treatment with omalizumab low-
ered free serum IgE in all patients in accordance with the
results of the omalizumab phase IIeIV clinical trial pro-
gram.3,4,7e10,15,16,23,24 Interestingly, the clinical benefit of
omalizumab was not related to serum concentrations of
free IgE or serum concentrations of omalizumab. A similar
pattern was seen in an earlier study following 23 patients
on long-term treatment (range 4.5 monthse7 years) with
omalizumab, including all omalizumab responders identi-
fied in this trial. All patients had responded to anti-IgE
Figure 1 Free serum IgE and omalizumab concentrations shown are mean  SEM concentrations of free serum IgE (ng/ml) and
omalizumab (mg/ml) during the whole treatment period. Black circles: Free serum IgE concentrations White circles: Omalizumab
concentrations.
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correlation between free serum IgE levels and pre-
treatment total IgE, omalizumab dose, or duration of
therapy.28 Free serum IgE was quantified at least twice to
evaluate variability concentrations showed a stable pattern
over time.
It cannot be excluded that an increase of omalizumab
doses in patients with free serum IgE above target range
may improve treatment results, more so since there is an
insignificant numerical difference between omalizumab
serum concentrations in responders and non-responders.
However, the similar magnitude of treatment effects in
responders below and above the 50 ng/ml threshold does
not support this hypothesis. Nevertheless, a long-term trial
to test the clinical potential of monitoring free serum IgE in
omalizumab patients is warranted. This further trial is
important since in vitro results demonstrate down-
regulation of Fc 3RI expression on human basophils during
in vivo treatment of atopic patients with anti-IgE.29 It is
tempting to speculate that long-term treatment with anti-
IgE may decrease the doses of omalizumab necessary to
uphold a sufficient treatment response. In line with this are
clinical reports that even three years after treatment with
omalizumab was stopped 12/18 patients reported improved
or unchanged asthma control compared with ongoing anti-
IgE treatment,30 further underlining the clinical relevance
of trials following free serum IgE in relation to response
criteria.
The results of this trial again highlight the question why
a significant number of patients with severe allergic asthma
carefully selected as recommended by recent guidelines2
did not respond to omalizumab treatment’, despite the
fact that serum free IgE concentrations were within or only
slightly above the therapeutic target range. A plausible
explanation suggests that in non-responders non-allergic
pathomechanisms dominate, while the clearly present
allergic disposition is not clinically relevant. Alternative
hypotheses suggest that the reduction of free serum IgE is
not the only mechanism responsible for the omalizumabeffects,25,31 that the ratio between total and specific IgE
may play a role,32 and that criteria used to define the
patient population in which a therapeutic trial with oma-
lizumab is justified are inadequate. The results of this study
confirm that in asthma the absolute reduction in free serum
IgE is insufficient to explain and predict clinical response
and to separate responders from non-responders. As yet,
a loose correlation between free serum IgE concentrations
and clinical benefit has only been shown in few studies21
and in models developed on the basis of single-dose
studies.10 Additional parameters need to be identified to
properly select patients that will likely benefit from
treatment with omalizumab. The hypothesis of clinically
relevant effects of omalizumab independent of IgE reduc-
tion is supported by observations that anti-IgE can be
effective in relatively low doses,33 in diseases character-
ized by serum total IgE concentrations outside of the dosing
table,34 and even in diseases without obvious allergic
pathomechanisms.35
This study has several limitations. Firstly, although
based on a valid sample calculation, the number of
patients included in this study is small. However, the
results of this study are well in accordance with results of
the omalizumab phase IIeIV clinical trials. Secondly, the
assay used to quantify free serum IgE has not yet been
validated in larger scale clinical trials prior to this study. It
may well be that the absolute free IgE serum concentra-
tions obtained with this assay differ from the assay(s) used
in the omalizumab clinical trials. Nevertheless, the pattern
of free serum IgE levels seen as part of the present study
are well in line with the results of these trials, indicating at
least a good proportional correlation. Thirdly, although the
observation period of 4 months is based on the omalizumab
license it cannot be excluded that the number of
responders will increase with duration of treatment. This is
true despite the fact that the percentage of responders in
this study is well in line with reports in other trials. Finally,
this was an open study, a fact known to influence patient’s
response to treatment, and there was no placebo control.
Free serum IgE in omalizumab-treated asthma 1499However, in the omalizumab study program there was no
effect of placebo on free serum IgE, and it was therefore
considered unethical to include a placebo arm in a study
including patients with severe asthma.
Conclusion
It is feasible to routinely monitor serum concentrations of
free IgE and omalizumab in patients with severe asthma
treated with omalizumab. In this study this information
does not predict clinical response nor does it add to the
clinical decision to continue or stop treatment. However,
routine measurements of free IgE may be clinically relevant
to demonstrate an adequate reduction in free IgE in
patients not responding to omalizumab therapy. For the
time being treatment responses to omalizumab have to be
judged solely based on clinical scoring systems. It remains
unclear if the absolute reduction of free IgE is the only
clinically relevant mechanism of action.
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